The Top 5 Biosimilar Articles for the Week of March 3

Number 5: The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases.

Number 4: February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.

Number 3: The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.

Number 2: Patients with inflammatory bowel disease (IBD) who switched from reference adalimumab (Humira) to a biosimilar under a mandatory nonmedical switching policy maintained long-term safety, efficacy, and treatment persistence comparable with those who remained on the originator drug, according to a Canadian study.

Number 1: Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara (ustekinumab), one of the most profitable drugs in the world.

To read all of these articles and more, visit centerforbiosimilars.com.